Programmed Sustained Release of Recombinant Human Bone Morphogenetic Protein-2 and Inorganic Ion Composite Hydrogel as Artificial Periosteum

ACS Appl Mater Interfaces. 2020 Feb 12;12(6):6840-6851. doi: 10.1021/acsami.9b18496. Epub 2020 Jan 30.

Abstract

Recombinant human bone morphogenetic protein-2 (rhBMP-2) and bioceramic are the widely used bioactive factors in treatment of bone defects, but these easily cause side effects because of uncontrollable local concentration. In this study, rhBMP-2 was grafted on the surface of mesoporous bioglass nanoparticles (MBGNs) with an amide bond and then photo-cross-linked together with methacrylate gelatin (GelMA); in this way, a GelMA/MBGNs-rhBMP-2 hydrogel membrane was fabricated to release rhBMP-2 in a controllable program during the early bone regeneration period and then release calcium and silicon ions to keep promoting osteogenesis instead of rhBMP-2 in a long term. In this way, rhBMP-2 can keep releasing for 4 weeks and then the ions keep releasing after 4 weeks; this process is matched to early and late osteogenesis procedures. In vitro study demonstrated that the early release of rhBMP-2 can effectively promote local cell osteogenic differentiation in a short period, and then, the inorganic ions can promote cell adhesion not only in the early stage but also keep promoting osteogenic differentiation for a long period. Finally, the GelMA/MBGNs-rhBMP-2 hydrogel shows a superior capacity in long-term osteogenesis and promoting bone tissue regeneration in rat calvarial critical size defect. This GelMA/MBGNs-rhBMP-2 hydrogel demonstrated a promising strategy for the controllable and safer use of bioactive factors such as rhBMP-2 in artificial periosteum to accelerate bone repairing.

Keywords: bone tissue regeneration; hydrogel; mesoporous bioglass; periosteum; rhBMP-2.

Publication types

  • Evaluation Study

MeSH terms

  • Animals
  • Bone Morphogenetic Protein 2 / administration & dosage*
  • Bone Morphogenetic Protein 2 / chemistry
  • Bone Morphogenetic Protein 2 / genetics
  • Bone Morphogenetic Protein 2 / metabolism
  • Bone Regeneration / drug effects
  • Calcium / administration & dosage*
  • Calcium / chemistry
  • Cell Adhesion / drug effects
  • Craniofacial Abnormalities / drug therapy*
  • Craniofacial Abnormalities / physiopathology
  • Delayed-Action Preparations / administration & dosage*
  • Delayed-Action Preparations / chemistry
  • Delayed-Action Preparations / metabolism
  • Drug Delivery Systems / methods*
  • Gelatin / chemistry
  • Humans
  • Hydrogels / chemistry
  • Nanoparticles / chemistry
  • Osteogenesis / drug effects
  • Periosteum / drug effects*
  • Periosteum / physiopathology
  • Rats
  • Rats, Sprague-Dawley
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / genetics
  • Recombinant Proteins / metabolism
  • Silicon / administration & dosage*
  • Silicon / chemistry
  • Transforming Growth Factor beta / administration & dosage*
  • Transforming Growth Factor beta / chemistry
  • Transforming Growth Factor beta / genetics
  • Transforming Growth Factor beta / metabolism

Substances

  • Bone Morphogenetic Protein 2
  • Delayed-Action Preparations
  • Hydrogels
  • Recombinant Proteins
  • Transforming Growth Factor beta
  • recombinant human bone morphogenetic protein-2
  • Gelatin
  • Calcium
  • Silicon